Medincell publishes its consolidated annual financial results
June 10, 2024
June 10, 2024
Publication of the financial results for the 2023-2024 fiscal year and videoconference on Monday, June 10, 2024
June 3, 2024
June 3, 2024
Medincell’s Partner Teva presented New Data Providing Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) from Invega Sustenna® (paliperidone palmitate)
June 3, 2024
June 3, 2024
Update of the 2024 financial calendar
May 27, 2024
May 27, 2024
[Replay] Videoconference: Company’s Latest News, Outlook, and R&D Activities
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
May 14, 2024
May 14, 2024
Medincell to Host Videoconference on May 15, 2024, at 10:30 AM CEST to Discuss Company’s Latest News, Outlook, and R&D Activities
May 13, 2024
May 13, 2024
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
May 8, 2024
May 8, 2024
Contacts
Medincell
David Heuzé
Head of Corporate and Financial Communications, and ESG
